Clinical Trial Update: An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B [Phase 3]

View source ↗

Summary

Biocad's ANB-002 is being studied in a Phase 3 open-label, single-dose trial in patients with Hemophilia B. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ANB-002

Snippet

Sponsor: Biocad | Conditions: Hemophilia B | Phase 3 | Status: RECRUITING